SVS:CA

Solarvest Announces Grant of Incentive Stock Options

(TheNewswire)



Vancouver, BC TheNewswire - February 19 2021 - SOLARVEST BIOENERGY INC. (TSXV:SVS) ("Solarvest" or the "Company"), is pleased to announce that, in accordance with the Company's Stock Option Plan, it has granted to certain directors, officers, employees and consultants, incentive stock options to purchase up to an aggregate of 3,360,000 common shares exercisable at a price of $0.40 per share for a period of three years from the grant date.  Of these stock options, 1,600,000 will be granted to Insiders of the Company, including a grant of 425,000 options to an officer and director who is also a Control Person of the Company and is exempt from shareholder approval accordance with section 5.7(1)(a) of MI 61-101.

The number of listed shares reserved for issuance under Solarvest's Stock Option Plan is 4,383,472 (10% of the issued and outstanding shares of the Company). There are no options outstanding and subsequent to the grant of options presented above, 1,023,472 options remaining available for issuance under the Plan.

Gerard Watts has agreed to accept the position of interim CFO, Gerard has been performing in the Comptroller position and will accept this extra responsibility while the company performs an executive search for a full time replacement.

About Solarvest:

Solarvest BioEnergy Inc. is an algae biotechnology company whose production platform provides it with an extremely flexible system capable of producing numerous valuable products from Organic Omega-3 fatty acids to therapeutic proteins/active ingredients. The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein, recombinant viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

S tatements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company's expectations and projections.

Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

With the debut of CWENCH Hydration™ in its first major Canadian grocer, Cizzle Brands anticipates that it will be able to further penetrate the mainstream consumer market alongside the specialty athletic and fitness-related markets. Starting this month, CWENCH Hydration™ mix packets will be offered in the pharmacy section of 47 Metro supermarkets across the province of Ontario.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

CWENCH Hydration Gains Distribution in Metro Supermarkets Across Ontario

With the debut of CWENCH Hydration™ in its first major Canadian grocer, Cizzle Brands anticipates that it will be able to further penetrate the mainstream consumer market alongside the specialty athletic and fitness-related markets. Starting this month, CWENCH Hydration™ mix packets will be offered in the pharmacy section of 47 Metro supermarkets across the province of Ontario.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks (Updated January 2025)

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three-year highs in response to breakthrough innovations and increased deals for biotech stocks on the NASDAQ.

After dropping to a low of 3,637.05 in October 2023, the index climbed to a high of 4,954.813 on September 19, 2024. While the NBI is trading down at 4,399.36 as of January 7, 2025, further growth could be in store in the future. However, the current economic environment means the biotech sector may have a complex road ahead.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.5 percent from now to 2034, reaching a valuation of US$4.61 trillion.

Keep reading...Show less

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025 . Robert A. Bradway chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025 . Robert A. Bradway chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×